AKBA Q1 2019 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$73M+58.2% YoY

Gross Profit

$41M57.0% margin

Operating Income

-$76M-104.5% margin

Net Income

-$72M-99.7% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

+21.4%

Cash Flow

Operating Cash Flow

-$138M

Free Cash Flow

-$140M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$891M

Total Liabilities

$324M

Stockholders' Equity

$566M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$46M	+58.2%
Gross Profit	$41M	-$15M	+367.6%
Operating Income	-$76M	-$24M	-210.1%
Net Income	-$72M	-$23M	-209.3%

Revenue Segments

Product

$23M100%